Trial Profile
Candesartan in the prevention of relapsing atrial fibrillation
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Apr 2011
Price :
$35
*
At a glance
- Drugs Candesartan cilexetil (Primary)
- Indications Atrial fibrillation
- Focus Pharmacodynamics; Therapeutic Use
- Acronyms CAPRAF
- 05 Jan 2007 Status change
- 19 Nov 2005 New trial record.